Business Wire

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

Jaa

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)1, and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

Non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in Western industrialized nations, and its more serious form NASH, is highly prevalent amongst patients with type 2 Diabetes. NASH is a major cause of liver fibrosis and cirrhosis and is an area of high unmet medical need with no treatments currently available. The high prevalence of type 2 diabetes and obesity is expected to make NASH one of the most common causes of advanced liver disorders in coming decades. 25% of the general adult population in the world has NAFLD and the prevalence of NASH has been found to range from 1.5% to 6.45% in current research, a number twice as high as 20 years ago.

In 2016 Boehringer Ingelheim obtained Fast Track Designation from the US Food and Drug Administration (FDA) for the development of BI 1467335 in NASH. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions which fill an unmet medical need. The designation provides opportunities for Boehringer Ingelheim to accelerate the development of this investigational drug candidate in NASH.

This Phase IIa trial is a multi-centre, double-blind design in 150 patients with clinical evidence of NASH. The primary objectives are to establish proof of clinical principle, investigate suitable dosing, and to evaluate the safety of BI 1467335. Patients will be randomized to either one of four dosages of BI 1467335 or to placebo for a 12-week treatment period.2 A subsequent Phase IIb study will seek to confirm and extend these findings.

Dr. Christopher Corsico, Chief Medical Officer Boehringer Ingelheim Boehringer Ingelheim commented, “Advancing BI 1467335 into Phase II clinical research is important news for patients with NASH. Boehringer Ingelheim is committed to developing novel therapeutics designed to address unmet medical need and improve public health. Boehringer Ingelheim looks forward to further studying this novel compound in NASH patients“.

Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for cardiometabolic disease patients. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes.

Pharmaxis CEO Mr. Gary Phillips said, “Pharmaxis selected Boehringer Ingelheim as our partner for PXS-4728A both because of the company’s reputation as a leader in cardio metabolic research and development, and its outstanding track record in advancing external research. Today’s announcement of the start of this Phase IIa clinical trial for NASH is excellent news and is very significant for Pharmaxis. It triggers the payment of an €18 million (A$27m) milestone to Pharmaxis and opens the path to a total of €195 million in milestone payments as the drug progresses through development and approval for this indication. The initiation of Phase II trials in a second indication later this year by Boehringer Ingelheim can bring the total potential value of the partnership with Boehringer Ingelheim to €418.5m (A$627m) plus sales milestones and high single digit earn-out payments on annual net sales.”

Please click on the link below for ‘Notes to Editors and References’:

http://www.boehringer-ingelheim.com/press-release/phase-iia-initiation-nash

Contact information

Contact:
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Phone: +49 (6132) 77-90815
reinhard.malin@boehringer-ingelheim.com
or
Pharmaxis
Felicity Moffatt
Phone: +61 418 677 701
felicity.moffatt@pharmaxis.com.au

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Citi Private Bank Congratulates Fernando Alonso on the 24 Hours of Le Mans Win18.6.2018 17:01Tiedote

Citi Private Bank ardently congratulates Fernando Alonso for his impressive win at The 24 Hours of Le Mans this past weekend. Mr. Alonso, who is also a two time Formula One World Champion, most recently competed and won the Six Hours of Spa-Francorchamps in May. In January he debuted at the Rolex 24 at Daytona. Previously he participated in the Indianapolis 500 in May of 2017. He was sponsored by Citi Private Bank for all four races. Alongside the Indianapolis 500 and the Monaco Grand Prix, Le Mans makes up one third of ‘the Triple Crown of Motor Racing’. Having already won Monaco twice, Mr. Alonso is on a quest to become only the second driver in history to complete the Triple Crown. “Fernando drove one the most thrilling races at Le Mans that I have ever seen. His stunning night time drive will likely go down as one of the greatest victories in motorsport’s history,” said Peter Clive Charrington, Global Head of Citi Private Bank. “Fernando possesses an unrelenting drive toward excell

Inteva Products Receives Top Innovation Award for Revolutionary Stitching Process18.6.2018 16:31Tiedote

Inteva Products, LLC, a leading global Tier One automotive supplier of engineered components and systems, received the top prize in the 2018 Innovation Awards presented by the European Association of Automotive Suppliers (CLEPA) at The Hague, Netherlands, on June 13. Inteva was recognized for its new real-time scanning process for the robotic stitching of automotive interiors. This innovative technology will be used on instrument panels for the 2019 Chevrolet Silverado and GMC Sierra pickup trucks. The new process enables “live” scanning and immediate adjustments to the program path of robotic stitching equipment as a component is being stitched. This approach aligns leading-edge advances in the use of lasers in automotive manufacturing with Inteva’s unique robotic stitching technologies. The advancement reduces the average cycle time of a stitched surface by approximately 20-30%. The 2018 CLEPA Innovation Awards, organized in cooperation with Deloitte, celebrate automotive excellence

P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity18.6.2018 15:25Tiedote

The Procter & Gamble Company (NYSE: PG) today advanced its commitment to gender equality through a series of new actions, commitments and partnerships to increase diversity throughout the creative supply chain, leading to more accurate and positive portrayals of women in advertising and media, and driving growth and social good. Women and girls are inaccurately or negatively portrayed in 29 percent of ads and media programs*, and women continue to be underrepresented behind the camera: only 32 percent of Chief Marketing Officers, 33 percent of Chief Creative Officers and a mere 10 percent of Commercial Directors are women. These issues persist despite evidence that gender-equal ads perform 10 percent higher in trust and 26 percent higher in sales growth*. To address these issues, P&G has called for an aspiration to achieve 100% accurate and positive portrayals of women in advertising and media, supported by equal representation of women and men in the creative supply chain. P&G is lead

Norsk Titanium Marks Milestone in U.S. Production18.6.2018 15:00Tiedote

Norsk Titanium (NTi), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, announced today a major milestone in qualified production. NTi’s Plattsburgh, New York Development and Qualification Center (PDQC) site was officially added to Boeing’s Qualified Producers List (QPL) on May 1 and initiated qualified production on May 15 by manufacturing its first part under the Boeing contract. This milestone is a culmination of recent company successes including certification under AS9100D and the October 2017 dedication of PDQC by New York Governor Andrew Cuomo. “We could not be prouder of our Plattsburgh, New York production operations as they put another stake in the ground for the continued success of Norsk Titanium and the state of New York,” said NTi’s Chief Operating Officer Tamara Morytko. “Receiving this qualification from Boeing, now qualifying two NTi sites for production across the globe, is a true vote of confidence in o

Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus18.6.2018 15:00Tiedote

Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking procedure to treat patients with progressive keratoconus. Keratoconus is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens and is the leading cause of penetrating keratoplasty (corneal transplant) in the United States1. The Phase 3 clinical trial, ACP-KXL-308, is a multicenter, randomized, controlled study of a novel corneal cross-linking procedure of 275 patients with progressive keratoconus across approximately 20 sites in the United States. As is typical for U.S. Food and Drug Administration (FDA) drug trials, investigational treatments are provided at no cost to participating patients. “As a practitioner who has treated many p

LG Chem Hosts Global Innovation Contest 2018 (GIC 2018)"Finding Innovations to Change the World"18.6.2018 14:00Tiedote

LG Chem (KRX: 051910) is exploring innovative technologies that will change the world. LG Chem announced that it would hold a Global Innovation Contest (GIC) for leading universities and research institutions around the world. This is the first time that a Korean chemical company is conducting technology contests for the entire world. From June 18th to September 30th, 2018, LG Chem will accept innovative technology ideas in five promising business areas: Energy, Environment, Functional materials, Bio technology and Platform technology. Global scholars and researchers who are interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcomed to participate and submit the technical proposal through the official website (www.rnd.lgchem.com/global/gic). LG Chem will select internal experts and selection committees to evaluate the proposals considering technology innovation, marketability, and price competitiveness. Selected assign

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme